Showing 9111-9120 of 10719 results for "".
New Products; Therapeutics Focus: Fungal Infections
https://practicaldermatology.com/columns/new-products/new-products-therapeutics-focus-fungal-infections/20631/The Importance of Employee Engagement
https://practicaldermatology.com/topics/general-topics/the-importance-of-employee-engagement/20639/The most valuable asset to your medical practice is not what you think.Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaReflections on 25 Years of Private Practice
https://practicaldermatology.com/topics/practice-management/reflections-on-25-years-of-private-practice/20670/Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/20729/New Products
https://practicaldermatology.com/columns/new-products/new-products/20745/Give Employee Feedback With Confidence
https://practicaldermatology.com/topics/practice-management/give-employee-feedback-with-confidence/20769/Ten tips to effectively communicate feedback to help employees grow and improve.Pearls for Treating NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/pearls-for-treating-nmsc/20775/Insights from DermTube.comCurrents
https://practicaldermatology.com/topics/psoriasis/currents/20773/Galderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema asso